Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
from SHASTA-3/4 evaluating plozasiran in severe hypertriglyceridemia (Q3 2026), CSF tau knockdown data for its CNS program ARO-MAPT (late Q3/early Q4), plus additional data from obesity programs ARO-INHBE and ARO-ALK7 , while running an event-driven SHASTA-5 study to assess pancreatitis outcomes. Waylivra launch and pricing strategy: Early commercial momentum shows ~100 prescriptions in ~10 weeks and positive early payer engagement, with Waylivra priced at $60,000/year positioned for a future SHTG expansion and pitched as a pancreatitis-prevention therapy that Arrowhead says offers deeper triglyceride reductions, cleaner safety signals, and once-quarterly dosing versus competitors. Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better. Want Diversified Upside in Biotechnology? Check out LABU Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD C
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]Yahoo! Finance
- Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 EventsBusiness Wire
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 2/5/26 - Form 10-Q
- 2/5/26 - Form 8-K
- 1/27/26 - Form ARS
- ARWR's page on the SEC website